SEC Form 4 · accession 0001140361-15-044782
NEVRO CORP · NVRO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Andre Walker
Officer — Senior VP,Research&Development
Period of report
Dec 14, 2015
Accepted (ET)
Dec 16, 2015 · 5:31 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001444380
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Dec 14, 2015 | M | 3,000 | $1.44 | A | 3,470 | D | |
| Common StockF2 | Dec 14, 2015 | S | 2,000 | $66.575 | D | 1,470 | D | |
| Common Stock | Dec 14, 2015 | S | 1,000 | $68.00 | D | 470 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F3 | $1.44 | Dec 14, 2015 | M | 3,000 | D | — | Jun 30, 2019 | Common Stock | 3,000 | 47,422 | D |
Explanation of responses
- F1The sales were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.
- F2The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $66.15 to $67.00, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F3100% of the shares subject to the option are fully vested and exercisable.